KR20040048166A - 성기능 개선 조성물 - Google Patents
성기능 개선 조성물 Download PDFInfo
- Publication number
- KR20040048166A KR20040048166A KR1020020075948A KR20020075948A KR20040048166A KR 20040048166 A KR20040048166 A KR 20040048166A KR 1020020075948 A KR1020020075948 A KR 1020020075948A KR 20020075948 A KR20020075948 A KR 20020075948A KR 20040048166 A KR20040048166 A KR 20040048166A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- weight
- seaweed
- sexual
- extract powder
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 230000006872 improvement Effects 0.000 title claims description 29
- 230000036299 sexual function Effects 0.000 title description 33
- 241001474374 Blennius Species 0.000 claims abstract description 37
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 19
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960001553 phloroglucinol Drugs 0.000 claims abstract description 12
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 claims abstract description 11
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 claims abstract description 11
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 claims abstract description 11
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 claims abstract description 11
- 239000007787 solid Substances 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 claims abstract description 9
- 241001512722 Ecklonia cava Species 0.000 claims abstract description 7
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 4
- 239000012141 concentrate Substances 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 8
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 8
- 240000006365 Vitis vinifera Species 0.000 claims description 8
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 8
- 235000007215 black sesame Nutrition 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008159 sesame oil Substances 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- DRZQFGYIIYNNEC-UHFFFAOYSA-N dieckol Chemical compound OC1=CC(O)=CC(OC=2C=3OC4=C(O)C=C(OC=5C(=CC(OC=6C=7OC8=C(O)C=C(O)C=C8OC=7C(O)=CC=6O)=CC=5O)O)C=C4OC=3C(O)=CC=2O)=C1 DRZQFGYIIYNNEC-UHFFFAOYSA-N 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000004575 stone Substances 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 244000299790 Rheum rhabarbarum Species 0.000 claims description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 3
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 240000002900 Arthrospira platensis Species 0.000 claims description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims description 2
- 229920002036 Dieckol Polymers 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000008429 bread Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims description 2
- 150000002338 glycosides Chemical class 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229920001339 phlorotannin Polymers 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229940082787 spirulina Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000258957 Asteroidea Species 0.000 claims 2
- 244000291564 Allium cepa Species 0.000 claims 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims 1
- 235000004936 Bromus mango Nutrition 0.000 claims 1
- 241000261585 Hadrobregmus pertinax Species 0.000 claims 1
- 240000007228 Mangifera indica Species 0.000 claims 1
- 235000014826 Mangifera indica Nutrition 0.000 claims 1
- 235000009184 Spondias indica Nutrition 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract description 35
- 201000001881 impotence Diseases 0.000 abstract description 35
- 230000001965 increasing effect Effects 0.000 abstract description 8
- 241000219094 Vitaceae Species 0.000 abstract description 6
- 235000021021 grapes Nutrition 0.000 abstract description 6
- 241000195473 Sargassum fulvellum Species 0.000 abstract description 4
- 241000264279 Sargassum fusiforme Species 0.000 abstract description 3
- 230000035807 sensation Effects 0.000 abstract description 2
- 241000206607 Porphyra umbilicalis Species 0.000 abstract 2
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 2
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 2
- 241000703939 Gracilariopsis longissima Species 0.000 abstract 1
- 241000199919 Phaeophyceae Species 0.000 abstract 1
- 235000019674 grape juice Nutrition 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 230000001856 erectile effect Effects 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 210000003899 penis Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 241001247821 Ziziphus Species 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 210000003556 vascular endothelial cell Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000035946 sexual desire Effects 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 4
- 241000195493 Cryptophyta Species 0.000 description 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000020774 essential nutrients Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 229940124595 oriental medicine Drugs 0.000 description 4
- -1 sodium nitroperoxide Chemical compound 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- 206010062542 Arterial insufficiency Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002036 chloroform fraction Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000005226 corpus cavernosum Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000009986 erectile function Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000006499 vasodilator function Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241001512723 Ecklonia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010052004 Organic erectile dysfunction Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000722085 Synanceia horrida Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940107702 grapefruit seed extract Drugs 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 150000003000 phloroglucinols Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 201000011264 priapism Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940070537 vitamin E 150 mg Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- GQDDNDAYOVNZPG-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C[C]2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3N=C21 GQDDNDAYOVNZPG-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
조성 | 실시예 1 | 실시예 2 | 실시예 3 | 비교예 1 | 비교예2 (placebo) |
물 | 48.7g | 35.3g | 35.7g | 36.6g | 물 35.5g전분 7g찹쌀가루 7.5g |
포도농축액 (65brix) | 0g | 7.0g | 7.0g | 7.0g | |
대추농축액 (50brix) | 0g | 6.0g | 6.0g | 6.0g | |
홍삼농축액 (60brix) | 0g | 0.4g | 0.0g | 0.4g | |
해조추출분말 | 1.3g | 1.3g | 1.3g | 0.0g |
실험자수(명) | 음경의 베이스(base) 경도가 60%를 넘는 실험지원자 | 발기 지속시간 개선정도가 41%이상인 지원자의 수 | |
실시예 1 | 15 | 9(60%) | 10(67%) |
비교예 1 | 10 | 5(50%) | 4(40%) |
실시예 2 | 15 | 12(80%) | 13(87%) |
실시예 3 | 15 | 9(60%) | 11(73%) |
비교예 2 | 13 | 2(15%) | 1(8%) |
건강한 남성 | 발기부전 환자군 | |||
복용 전 | 복용 8주후 | 복용 전 | 복용 8주후 | |
FMD(%) | 6.12 ±0.52 | 6.13 ±0.76 | 5.46 ±1.70 | 7.83 ±1.95 |
NMD(%) | 11.4 ±2.00 | 11.8 ±2.22 | 7.94 ±1.09 | 11.8 ±1.72 |
복용전 | 복용후 | 복용전 | 복용후 | 복용전 | 복용후 | |||
case 1 | 5 | 5 | case 17 | 36 | 60 | case 33 | 40 | 53 |
case 2 | 53 | 49 | case 18 | 20 | 56 | case 34 | 16 | 15 |
case 3 | 40 | 58 | case 19 | 29 | 39 | case 35 | 15 | 35 |
case 4 | 35 | 43 | case 20 | 13 | 11 | case 36 | 17 | 24 |
case 5 | 19 | 21 | case 21 | 40 | 32 | case 37 | 12 | 17 |
case 6 | 35 | 39 | case 22 | 25 | 52 | case 38 | 19 | 16 |
case 7 | 23 | 29 | case 23 | 14 | 30 | case 39 | 20 | 19 |
case 8 | 29 | 41 | case 24 | 13 | 19 | case 40 | 18 | 32 |
case 9 | 46 | 53 | case 25 | 12 | 10 | case 41 | 29 | 40 |
case 10 | 41 | 39 | case 26 | 18 | 40 | case 42 | 36 | 45 |
case 11 | 30 | 40 | case 27 | 11 | 11 | case 43 | 32 | 38 |
case 12 | 32 | 57 | case 28 | 19 | 45 | case 44 | 23 | 40 |
case 13 | 14 | 13 | case 29 | 31 | 42 | case 45 | 33 | 32 |
case 14 | 47 | 53 | case 30 | 24 | 41 | case 46 | 19 | 18 |
case 15 | 32 | 35 | case 31 | 23 | 29 | |||
case 16 | 58 | 52 | case 32 | 35 | 59 |
호전 | 불량 | 무변화 | Total | |
발기능력 | 23(50%) | 11(24%) | 12(26%) | 46(100%) |
극치감능력 | 23(50%) | 9(20%) | 14(30%) | 46(100%) |
성교만족도 | 33(72%) | 5(11%) | 8(17%) | 46(100%) |
성적욕구 | 25(54%) | 11(24%) | 10(22%) | 46(100%) |
총체적만족도 | 31(67%) | 5(11%) | 10(22%) | 46(100%) |
Claims (7)
- 고형분을 기준으로 푸코스테롤을 0.05%이상 및 플로로글루시놀계 화합물 10%이상 함유하는 해조추출분말을 적어도 0.1중량%를 포함하는 것을 특징으로 하는 성기능 개선 조성물.
- 제1항에 있어서, 상기 조성물이 고형분을 기준으로 해조 추출분말 0.1∼50중량%, 포도농축액 1∼50중량%, 홍삼농축액 0.1∼10중량%, 및 대추농축액 1∼50중량%으로 구성되는 것을 특징으로 하는 성기능 개선 조성물.
- 제1항에 있어서, 상기 조성물이 고형분을 기준으로 해조 추출분말 0.1∼50중량%, 비타민 E 5∼50중량% 및 검은 깨기름 5∼50중량%로 구성되는 것을 특징으로 하는 성기능 개선 조성물.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 해조추출분말은 미역, 모자반, 갈래곰보, 파래, 감태, 톳, 다시마, 대황, 김, 꼬시래기, 돌가사리, 둥근돌김, 뜸부기, 매생이, 불등가사리, 석묵, 스피루리나, 우뭇가사리, 진두발, 청각, 클로렐라 및 곰피로 이루어진 군으로부터 하나 또는 그 이상 선택된 해조류로부터 얻는 것을 특징으로 하는 조성물.
- 제1항 있어서, 상기 플로로글루시놀계 화합물은 엑콜, 디엑콜, 플로로탄닌 A, 플로로푸코푸로엑콜, 7,7'-바이엑콜, 9,9'-바이엑콜 및 이의 배당체를 포함하는 것을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 조성물은 약품, 건강보조식품, 특수영양식품, 음료 및 주류, 식품첨가제, 과자 또는 빵에 첨가되는 것을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 조성물의 제형이 정제, 캅셀, 환제 또는 과립제인 특징으로 하는 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0075948A KR100518179B1 (ko) | 2002-12-02 | 2002-12-02 | 성기능 개선 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0075948A KR100518179B1 (ko) | 2002-12-02 | 2002-12-02 | 성기능 개선 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040048166A true KR20040048166A (ko) | 2004-06-07 |
KR100518179B1 KR100518179B1 (ko) | 2005-09-29 |
Family
ID=37343072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-0075948A KR100518179B1 (ko) | 2002-12-02 | 2002-12-02 | 성기능 개선 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100518179B1 (ko) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100966128B1 (ko) * | 2008-01-10 | 2010-06-25 | 대구가톨릭대학교산학협력단 | 고지혈증 및 당뇨 치료용 대황 효소추출물, 대황정제환 및이의 제조방법 |
KR200453804Y1 (ko) * | 2009-04-23 | 2011-05-30 | 안중식 | 일체형 도어 손잡이를 갖는 슬라이드형 욕실 수납장 |
US20120189722A1 (en) * | 2009-09-17 | 2012-07-26 | Fabrizio Iacono | Dietary supplement stimulating the male sexual function |
KR20170118427A (ko) * | 2016-04-15 | 2017-10-25 | 한국인스팜(주) | 야관문과 홍삼을 함유한 남성갱년기 증후군 개선용 건강식품조성물 |
KR20190086386A (ko) * | 2018-01-12 | 2019-07-22 | 주식회사 보타메디 | 플로로탄닌을 유효성분으로 포함하는 여성 성기능 개선용 조성물 |
KR102180363B1 (ko) * | 2019-05-14 | 2020-11-19 | 주식회사 대화바이오 | 검은 참깨와 효모 가수분해물을 함유하는 남성 성기능 개선용 조성물 |
JP2020536590A (ja) * | 2017-10-13 | 2020-12-17 | クリスタルファルマ・ソチエタ・ア・レスポンサビリタ・リミタータ | 老化によって引き起こされる女性の障害を緩和するためのサプリメント |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140081339A (ko) * | 2012-12-21 | 2014-07-01 | 부경대학교 산학협력단 | 푸코스테롤을 유효성분으로 포함하는 퇴행성 신경질환 예방 또는 치료용 약제학적 조성물 |
-
2002
- 2002-12-02 KR KR10-2002-0075948A patent/KR100518179B1/ko active IP Right Grant
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100966128B1 (ko) * | 2008-01-10 | 2010-06-25 | 대구가톨릭대학교산학협력단 | 고지혈증 및 당뇨 치료용 대황 효소추출물, 대황정제환 및이의 제조방법 |
KR200453804Y1 (ko) * | 2009-04-23 | 2011-05-30 | 안중식 | 일체형 도어 손잡이를 갖는 슬라이드형 욕실 수납장 |
US20120189722A1 (en) * | 2009-09-17 | 2012-07-26 | Fabrizio Iacono | Dietary supplement stimulating the male sexual function |
US8609155B2 (en) * | 2009-09-17 | 2013-12-17 | Tradapharma Sagl | Dietary supplement stimulating the male sexual function |
KR20170118427A (ko) * | 2016-04-15 | 2017-10-25 | 한국인스팜(주) | 야관문과 홍삼을 함유한 남성갱년기 증후군 개선용 건강식품조성물 |
JP2020536590A (ja) * | 2017-10-13 | 2020-12-17 | クリスタルファルマ・ソチエタ・ア・レスポンサビリタ・リミタータ | 老化によって引き起こされる女性の障害を緩和するためのサプリメント |
KR20190086386A (ko) * | 2018-01-12 | 2019-07-22 | 주식회사 보타메디 | 플로로탄닌을 유효성분으로 포함하는 여성 성기능 개선용 조성물 |
KR102180363B1 (ko) * | 2019-05-14 | 2020-11-19 | 주식회사 대화바이오 | 검은 참깨와 효모 가수분해물을 함유하는 남성 성기능 개선용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR100518179B1 (ko) | 2005-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105233010A (zh) | 一种补肾壮阳酒及其制备方法 | |
CN100394859C (zh) | 爽身保健茶 | |
CN105232907A (zh) | 一种补肾壮阳饮料及其制备方法 | |
CN102366595A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
US20110189319A1 (en) | Lifeforce liquid supplement | |
KR100518179B1 (ko) | 성기능 개선 조성물 | |
CN115317574A (zh) | 一种用于治疗高尿酸血症的组合物及其应用 | |
CN105250913B (zh) | 一种治疗蛋鸡脂肪肝综合症的药物组合物 | |
CN107006856A (zh) | 一种增强耐力、提高抗缺氧耐受力营养剂及其制备方法 | |
KR101788253B1 (ko) | 고량강, 풀솜대 및 흑마늘을 유효성분으로 포함하는 남성 성기능 개선용 조성물 | |
CN112791175A (zh) | 提高人体新陈代谢机能和排出代谢废物的中西药组合物及其制备方法 | |
CN102090637A (zh) | 一种含有胶原蛋白的复方营养粉 | |
KR101999675B1 (ko) | 관상동맥성 심장질환의 예방과 치료용 생약조성물 | |
WO2012063198A1 (en) | Compositions for the prevention and treatment of erectile dysfunction and impotence and for improving sport performance | |
CN101336705B (zh) | 保健食品及其制备方法 | |
RU2485965C2 (ru) | Компартаментспецифическая комбинация растительных экстрактов из гинкго билоба и женьшеня, обладающая двойным действием | |
KR102238009B1 (ko) | 노니가 함유된 홍삼 가공품 및 이의 제조방법 | |
CN101897747A (zh) | 一种用于缓解视疲劳的中药保健品及其制备方法 | |
CN109289017A (zh) | 用于清理血管和血液的组合物及制备方法 | |
KR20030049063A (ko) | 발기부전증 예방 및 치료용 조성물 | |
KR20020089251A (ko) | 다이어트에 유용한 첩부용 조성물 및 첩부제 | |
RU2792449C2 (ru) | Состав фиточая, содержащего биологически активные добавки | |
CN108883145A (zh) | 一种内服外涂结合治疗爱滋病、肿瘤的药剂 | |
Arya | Food is your Medicine | |
JP3557548B2 (ja) | 活力促進食品およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120921 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20131023 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140923 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150923 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20160923 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170922 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20181029 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20190923 Year of fee payment: 15 |